Single-dose amoxicillin therapy of acute uncomplicated urinary tract infections in women. 1984

N E Tolkoff-Rubin, and M E Wilson, and P Zuromskis, and I Jacoby, and A R Martin, and R H Rubin

Of 210 women who were experiencing dysuria, frequent urination, pyuria, and significant bacteriuria and who were treated with a single 3-g dose of amoxicillin, 165 (79%) were cured of their original infections. Patients with infections that were negative by antibody-coated-bacteria assay were cured at a significantly higher rate than those with infections that were positive by antibody-coated-bacteria assay (90 versus 59%; P less than 0.001). Similarly, those with infections caused by amoxicillin-susceptible organisms were cured at a significantly higher rate than those with infections caused by resistant organisms (85 versus 50%; P less than 0.001). Of 27 patients who had infections caused by amoxicillin-susceptible organisms and who had relapses after single-dose therapy, 14 (52%) had relapses again after a conventional 10-day course of therapy, although all responded to a 6-week course. An additional 27 patients experiencing dysuria, frequent urination, and pyuria but who had a lower number of uropathogens in the urine (10(2) to 10(4.5)/ml of urine) were treated with single-dose therapy, with a 100% eradication of organisms and an 89% rate of symptomatic relief.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D004756 Enterobacteriaceae Infections Infections with bacteria of the family ENTEROBACTERIACEAE. Enterobacterial Infections,Cronobacter Infections,Infections, Enterobacteriaceae,Infections, Enterobacterial,Cronobacter Infection,Enterobacteriaceae Infection,Enterobacterial Infection,Infection, Cronobacter,Infection, Enterobacteriaceae,Infection, Enterobacterial,Infections, Cronobacter
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

N E Tolkoff-Rubin, and M E Wilson, and P Zuromskis, and I Jacoby, and A R Martin, and R H Rubin
April 1983, The Journal of pediatrics,
N E Tolkoff-Rubin, and M E Wilson, and P Zuromskis, and I Jacoby, and A R Martin, and R H Rubin
January 1992, Infection,
N E Tolkoff-Rubin, and M E Wilson, and P Zuromskis, and I Jacoby, and A R Martin, and R H Rubin
May 1985, The New Zealand medical journal,
N E Tolkoff-Rubin, and M E Wilson, and P Zuromskis, and I Jacoby, and A R Martin, and R H Rubin
December 1982, The American journal of medicine,
N E Tolkoff-Rubin, and M E Wilson, and P Zuromskis, and I Jacoby, and A R Martin, and R H Rubin
July 1994, International journal of antimicrobial agents,
N E Tolkoff-Rubin, and M E Wilson, and P Zuromskis, and I Jacoby, and A R Martin, and R H Rubin
November 1995, Journal of chemotherapy (Florence, Italy),
N E Tolkoff-Rubin, and M E Wilson, and P Zuromskis, and I Jacoby, and A R Martin, and R H Rubin
January 1988, Drug intelligence & clinical pharmacy,
N E Tolkoff-Rubin, and M E Wilson, and P Zuromskis, and I Jacoby, and A R Martin, and R H Rubin
December 1981, The Journal of pediatrics,
N E Tolkoff-Rubin, and M E Wilson, and P Zuromskis, and I Jacoby, and A R Martin, and R H Rubin
January 1990, Chemotherapy,
N E Tolkoff-Rubin, and M E Wilson, and P Zuromskis, and I Jacoby, and A R Martin, and R H Rubin
July 1989, Journal of chemotherapy (Florence, Italy),
Copied contents to your clipboard!